Skip to content

Study of Chlorhexidine Gluconate as a Preoperative Antisepsis

Comparison of Chlorhexidine Gluconate and Povidone Iodine as a Preoperative Antisepsis in Clean-contaminated Abdominal Surgery : a Randomized Prospective Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01495117
Acronym
CHG
Enrollment
534
Registered
2011-12-19
Start date
2011-10-31
Completion date
2014-10-31
Last updated
2016-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection

Keywords

surgical site infection, chlorhexidine gluconate, povidone iodine

Brief summary

The purpose of this study is to determine which drug (chlorhexidine gluconate vs. povidone iodine) as a preoperative antisepsis in clean-contaminated abdominal surgery (liver, hepatobiliary, small or large bowel, stomach) is effective.

Interventions

DRUGPovidone-Iodine

7.5% povidone iodine soaping 10% povidone iodine painting

DRUGChlorhexidine gluconate

4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting

Sponsors

Seung Duk Lee
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Resection of following organs (clean-contaminated open surgery) * Liver, Pancreas, Bile duct, Duodenum * Stomach * Colon, Small bowel 2. Aged 20 - 85 years old 3. Use Prophylactic antibiotics 4. Use Preoperative bowel preparation 5. Elective operation 6. ASA classification 1-2 ASA I : no known systemic disease ASA II : single systemic disease & mild or well controlled ASA III : multiple systemic diseases or moderately controlled systemic disease ASA IV : poorly controlled systemic diseases 7. adequate organ functions defined as indicated below: * WBC 3000 \ 12 000/mm3 * \> Hb 8.0 g/dl * \> Plt 100 000/mm3 * \< Cr 1.2 mg/dl

Exclusion criteria

1. allergy to chlorhexidine or povidone 2. clean surgery or contaminated surgery 3. patients who cannot be followed up during 1 month 4. patients taking immunosuppressant drugs or chemotherapy agents 5. emergent surgery and reoperation 6. uncontrolled diabetes, BMI \> 30 kg/m2 7. vulnerable patients

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with Surgical Site infection within 1monthwithin 1 monthCheck the surgical site infection (SSI) rate within one month Superficial SSI, Deep SSI, Organ Site SSI decided by physician CDC Definition in 1999 Superficial incisional infection : involving only the skin or subcutaneous tissue of the incision Deep incisional Infection : involving the deep tissues (i.e. fascial and muscle layers) Organ Space Infection : involving any part of the anatomy (i.e. organ/space), other than the incision

Secondary

MeasureTime frameDescription
Identify the infection sourcewithin 1monthIf SSI occur, we check the infection source including types of bacteriae using culture.
Number of patients with Drug Side effect.Within 1 monthWe check the side effect of our drugs including chlorhexidine and povidione iodine. For example, itching sense, pruritis, ulticaria, redness, anaphylaxis
Number of patients with the postoperative sepsis induced by wound infectionwithin 1 monthDefinition of Sepsis 1. Proven infection (by culture, stain) or a clinical syndrome pathognomonic for infection (WBC, imaging finding or petechiae, purpura, or purpura fulminans) 2. Body temperature (\<36 or \>38 Celsus Degree) 3. Heart rate \> 90 beats per minute 4. Respiratory rate \> 20 breaths per minute or, on blood gas, a PaCO2 less than 32 mmHg 5. WBC count \<4000 cells/mm3 or \>12000 cells/mm3

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026